The efficacy and safety of low-dose diclofenac sodium 0.1% gel for the symptomatic relief of pain and erythema associated with superficial natural sunburn

European Journal of Dermatology

Volumn 14, Issue 4, 2004, Pages 238-246

  Magnette, John ^a   Kienzler, Jean Luc ^a   Alekxandrova, Ioulia ^a   Savaluny, Elly ^a   Khemis, Abdallah ^b   Amal, Saïd ^c   Trabelsi, Mohamed ^c   Césarini, Jean Pierre ^d  

^a Department of Clinical Pharmacology   (Switzerland)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c Department of Neurology   (Morocco)

^d FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

Author keywords

Diclofenac Na 0.1 gel; First degree sunburn; NSAID; Phototype II IV

Indexed keywords

DICLOFENAC; DRUG VEHICLE; IBUPROFEN; PARACETAMOL; STEROID;

ABDOMINAL PAIN; ADULT; ANALGESIA; ARTICLE; BACKACHE; BLISTER; BODY SURFACE; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COOLING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; GASTRITIS; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GEL; HEADACHE; HUMAN; INFECTION; INJURY; INSECT BITE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PAIN; PAIN ASSESSMENT; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RIGOR; SUN EXPOSURE; SUNBURN; SUNLIGHT; ULTRAVIOLET RADIATION;

ADMINISTRATION, CUTANEOUS; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; DOUBLE-BLIND METHOD; FEMALE; GELS; HUMANS; MALE; SEVERITY OF ILLNESS INDEX; SUNBURN; TREATMENT OUTCOME;

EID: 3543108575     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Hruza LL, Pentland AP. Mechanisms of UV-induced inflammation. J Invest Dermatol 1993; 100: 35S-41S.
2. Gilchrest BA, Soter NA, Stoff JS, Mihm MC Jr. The human sunburn reaction: histologic and biochemical studies. J Am Acad Dermatol 1981; 5: 411-22.
3. Wang L, Eng W, Cockerell CJ. Effects of ultraviolet irradiation on inflammation in the skin. Advances in Dermatology. Mosby Inc. 2002; 18: 247-86.
4. Clydesdale GJ, Dandie GW, Muller HK. Ultraviolet light induced injury: immunological and inflammatory effects. Immunol Cell Biol 2001; 79: 547-68.
5. Kripke ML. Immunological effects of ultraviolet radiation. J Dermatol 1991; 18: 429-33.
6. Rivas JM, Ullrich SE. The role of IL-4, IL-10, and TNF-alpha in the immune suppression induced by ultraviolet radiation. J Leukoc Biol 1994; 56: 769-75.
7. Eberlein-Konig B, Jager C, Przybilla B. Ultraviolet B radiation-induced production of interleukin 1alpha and interleukin 6 in a human squamous carcinoma cell line is wavelength-dependent and can be inhibited by pharmacological agents. Br J Dermatol 1998; 139: 415-21.
8. Black AK, Hensby CN, Greaves MW. Increased levels of 6-oxo-PGF1 alpha in human skin following ultraviolets irradiation. Br J Clin Pharmacol 1982; 13: 351-4.
9. Black AK, Greaves MW, Hensby CN, Plummer NA, Warin AP. The effects of indomethacin an arachidonic acid and prastaglandins E2 and F2 alpha levels in human skin 24 h after UVB and UCC irradiation. Br J Clin Pharmacol 1978; 6: 261-6.
10. Black AK, Greaves MW, Hensby CN, Plummer NA. Increased prostaglandins E2 and F2-alpha in human skin at 6 and 24 h after ultraviolet B irradiation (290-320 nm). Br J Clin Pharmacol 1978; 5: 431-6.
11. Greaves MW, Sondergaard J. Pharmacologic agents released in ultraviolet inflammation studied by continuous skin perfusion. J Invest Dermatol 1970; 54: 365-7.
12. Driscoll MS, Wagner RF Jr. Clinical management of the acute sunburn reaction. Cutis 2000; 66: 53-8.
13. Lichtenstein J, Flowers F, Sherertz EF. Nonsteroidal antiinflammatory drugs. Their use in dermatology. Int J Dermatol 1987; 26: 80-7.
14. Schwarz T, Gschnait F, Greifer F. Photoprotective effect of topical indomethacin - an experimental study. Dermatologica 1985; 171: 450-8.
15. Farr PM, Diffey BL. A quantitative study of the effect of topical indomethacin on cutaneous erythema induced by UVB and UVC radiation. Br J Dermatol 1986; 115: 453-66.
16. Ibbotson SH, Diffey BL, Farr PM. The effect of topical indomethacin on ultraviolet-radiation-induced erythema. Br J Dermatol 1996; 135: 523-7.
17. Edwards EK Jr, Horwitz SN, Frost P. Reduction of the erythema response to ultraviolet light by nonsteroidalantiinflammatory agents. Arch Dermatol Res 1982; 272: 263-7.
18. Juhlin L, Shroot B. Effect of drugs on the early and late phase UV erythema. Acta Derm Venereol 1992; 72: 222-3.
19. Stern RS, Dodson TB. Ibuprofen in the treatment of UV-B-induced inflammation. Arch Dermatol 1985; 121: 508-12.
20. Wilgus TA, Parrett ML, Ross MS, Tober KL, Robertson FM, Oberyszyn TM. Inhibifion of ultraviolet light B-induced cutaneous inflammation by a specific cyclooxygenase-2 inhibitor. Adv Exp Med Biol 2002; 507: 85-92.
21. Qian C, Hwang SB, Libertine-Garahan L, Eckman JB, Cai X, Scannell RT, Yeh CG. Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res 2001; 44: 213-20.
22. Burke JR, Davern LB, Stanley PL, Gregor KR, Banville J, Remillard R, Russell JW, Brassil PJ, Witmer MR, Johnson G, Tredup JA, Tramposch KM. BMS-229724 is a tight-binding inhibitor of cytosolic phospholipase A2 that acts at the lipid/water interface and possesses anti-inflammatory activity in skin inflammation models. J Pharmacol Exp Ther 2001; 298: 376-85.
23. Grundmann JU, Bockelmann R, Bonnekoh B, Gollnick HP. UV erythema reducing capacity of mizolastine compared to acetylsalicylic acid or both combined in comparison to indomethacin. Photochem Photobiol 2001; 74: 587-92.
24. Bickel A, Dorfs S, Schmelz M, Forster C, Uhl W, Handwerker HO. Effects of antihyperalgesic drugs on experimentally induced hyperalgesia in man. Pain 1998; 76: 317-25.
25. Sycha T, Gustorff B, Lehr S, Tanew A, Eichler HG, Schmetterer L. A simple pain model far the evaluation af analgesic effects of NSAIDs in healthy subjects. Br J Clin Pharmacol 2003; 56: 165-72.
26. th ed. Oxford: Blackwell Science 1998.
27. Jarvis B, Figgitt DP. Topical 3% diclofenac in 2.5% hyaluronic acid gel: a review of its use in patients with actinic keratoses. Am J Clin Dermatol 2003; 4: 203-13.
28. Friedman ES, LaNatra N and Stiller MJ. NSAIDs in dermatologic therapy: review and preview. J Cutan Med Surg 2002; 6: 449-59.
29. th Congress of EACPT, Istanbul, June 2003.
30. Fitzpatrick TB. The validity and practicality of skin types I through VI. Arch Dermatol 1988; 124: 869-71.
31. Duteil L, Queille C, Poncet M, Ortonne JP, Czernielewski J. Objective assessment of topical corticosteroids and non-steroidal anti-inflammatory drugs in methyl-nicotinate-induced skin inflammation. Clin Exp Dermatol 1990; 15: 195-9.
32. Altmeyer P, Modification of experimental UV erythema by external steroids-a reflex photometric study. Arch Dermatol Res 1977; 258: 203-9.
33. Malvy D, Guinot C, Preziosi P, Vaillant L, Tenenhaus M, Galan P, Tschachler E, Hercberg S. Epidemiological determinants of skin photoageing in a general adult population in France. Rev Epidemiol Sante Publique 2000; 48: 585-8.
34. Duteil L, Queille-Roussel C, Lorenz B, Thieroff-Ekerdt R, Ortonne JP. A randomized, controlled study of the safety and efficacy of topical corticosteroid treatments of sunburn in healthy volunteers. Clin Exp Dermatol 2002; 27: 314-8.
35. Schaffler K, Beckers C, Unkauf M, Kyrein HJ. Dimethindene maleate in the treatment of sunburn. A double-blind, placebo-controlled pilot study. Arzneimittelforschung 1999; 49: 374-9.
36. Dalili H, Adriani J. The efficacy of local anesthetics in blocking the sensations of itch, burning, and pain in normal and "sunburned" skin. Clin Pharmacol Ther 1971; 12: 913-9.
37. Arendt-Nielsen L, Sumikura H. From pain research to pain treatment: role of human pain models. J Nippon Med Sch 2002; 69: 514-24.
38. Huskisson EC. Measurement of pain. Lancet 1974; 2: 1127-31.
39. Harrison GI, Young AR, McMahon SB. Ultraviolet radiation-induced inflammation as a model for cutaneous hyperalgesia. J Invest Dermatol 2004; 122: 183-9.
40. Gustarff B, Anzenhofer S, Sycha T, Lehr S, Kress HG. The sunburn pain model: the stability or primary and secondary hyperalgesia over 10 hours in a crossover setting. Anesth Analg 2004; 98: 173-7.
41. Benrath J, Gillardon F, Zimmermann M. Differential time courses of skin blood flow and hyperalgesia in the human sunburn reaction following ultraviolet irradiation of the skin. Eur J Pain 2001; 5: 155-67.
42. Hoffmann RT, Schmelz M. Time course af UVA-and UVB-induced inflammation and hyperalgesia in human skin. Eur J Pain 1999; 3: 131-9.
43. Pedersen JL, Kehlet H. Hyperalgesia in a human model of acute inflammatary pain: a methodological study. Pain 1998; 74: 139-51.
44. Treede RD, Meyer RA, Raja SN, Campbell JN. Peripheral and central mechanisms of cutaneous hyperalgesia. Prog Neurobiol 1992; 38: 397-421.
45. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001; 413: 203-10.
46. Ma W, Eisenach JC. Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain. Eur J Neurosci 2002; 15 (6): 1037-47.
47. Levine JD, Reichling DB. Peripheral mechanisms of inflammatory pain. In: Wall PD, Melzack R (eds). Textbook of Pain. New York: Churchill Livingstone, 1999; pp 59-84.
48. Burian M, Tegeder I, Seegel M, Geisslinger G. Peripheral and central antihyperalgesic effects of diclofenac in a model of human inflammatory pain. Clin Pharmacol Ther 2003; 74: 113-20.
49. Bickel A, Dorfs S, Schmelz M, Forster C, Uhl W, Handwerker HO. Effects of antihyperalgesic drugs on experimentally induced hyperalgesia in man. Pain 1998; 76: 317-25.
50. Gougat J, Ferrari B, Sarran L, Planchenault C, Poncelet M, Maruani J, Alonso R, Cudennec A, Croci T, Guagnini F, Urban-Szabo K, Martinolle Jp J, Soubrie P, Finance O, Le Fur G. SSR240612, a new non-peptide antagonist of the bradykinin B1 receptor. Biochemical and pharmacological characterization. J Pharmacol Exp Ther 2004 Jan 27.
51. Kiefer W, Dannhardt G. COX-2 inhibition and the control of pain. Curr Opin Investig Drugs 2002; 3: 1348-58.